Protective effects of aqueous fruit extract from sea buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) on haloperidol-induced orofacial dyskinesia and neuronal alterations in the striatum

Case Reports and Clinical Practice Review

Volumn 16, Issue 8, 2010, Pages

  Batool, Farhat ^a   Shah, Asad Hussain ^b   Ahmed, Syed Dilnawaz ^b   Saify, Zafar Saeid ^a   Haleem, Darakhshan Jabeen ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b UNIVERSITY OF AZAD JAMMU AND KASHMIR   (Pakistan)

Author keywords

Haloperidol; Receptors; Schizophrenia; Sea buckthorn (Hippophae rhamnoides); Striatum; Vacuous chewing movements postsynaptic dopamine D2

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HALOPERIDOL; HIPPOPHAE RHAMNOIDES EXTRACT; HOMOVANILLIC ACID; SODIUM CHLORIDE; ACETIC ACID; DIHYDROXYPHENYL ACETIC ACID; UNCLASSIFIED DRUG; PLANT EXTRACT; PROTECTIVE AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BRAIN LEVEL; CATALEPSY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG SYNTHESIS; EXPLORATORY BEHAVIOR; HIPPOPHAE RHAMNOIDES; LOCOMOTION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OROFACIAL DYSKINESIA; RAT; TARDIVE DYSKINESIA; CAGE; CELL LEVEL; DYSKINESIA; EXPERIMENT; EXTRACT; FEEDING; FEEDING APPARATUS; FRUIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INJECTION; MASTICATION; MOVEMENT (PHYSIOLOGY); NERVE DEGENERATION; TUBE; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NEOSTRIATUM; NERVE CELL; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYTOTHERAPY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; CATALEPSY; DOPAMINE; EXPLORATORY BEHAVIOR; FRUIT; HALOPERIDOL; HIPPOPHAE; HOMOVANILLIC ACID; MALE; MOTOR ACTIVITY; MOVEMENT DISORDERS; NEOSTRIATUM; NEURONS; PHYTOTHERAPY; PLANT EXTRACTS; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 77955339360     PISSN: 15076164     EISSN: 16433742     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Yang B, Kallio H: Composition and physiological effects of Sea buckthorn (Hippophae) lipids. Trends Food Sci Technol, 2002; 13: 160-67
2. Zeb A: Chemical and nutritional constituents of Sea buckthorn juice. Pakistan J Nutr, 2004; 3: 99-106
3. Zheng RX, Xu XD, Tian Z, Yang JS: Chemical constituents from the fruits of Hippophae rhamnoides. Nat Prod Res, 2009; 23: 1451-56
4. Shah AH, Ahmed SD, Sabir M et al: Biochemical and nutritional evaluations of Sea buckthorn (Hippophae rhamonides L. spp. Turkestanica) from different locations of Pakistan. Pakistan J Botany, 2007; 39: 2059-65
5. Tiitinen KM, Hakala MA, Kallio HP: Quality components of sea buckthorn Hippophae rhamnoides) varieties. J Agric Food Chem, 2003; 53: 1692-99
6. Li TSC, Schroeder WR: Sea buckthorn (Hippophae rhamnoides): a multipurpose plant. Hort-Technology, 1996; 6: 370-80
7. Beveridge T, Harrison JE, Drover J: Processing effects on the composition of Sea buckthorn juice from Hippophae rhamnoides. L. Cv. Indian summer. J Agric Food Chem, 2002; 50: 113-16
8. Bernath J, Foldesi D: Using Sea buckthorn oil in treating burns. Sov Med, 1992; 11: 137-38
9. Batool F, Shah AH, Ahmed SD et al: Possible anxiolytic profile of aqueous fruit extracts of a medicinal plant Sea buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) in experimental models. Pakistan J Botany, 2009a; 40: 2791-800
10. Batool F, Shah AH, Ahmed SD, Haleem DJ: Oral supplementation of Sea buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) fruit extract modifies haloperidol induced behavioral deficits and increases brain serotonin metabolism. J Food and Drug analysis, 2009b; 17: 257-63
11. Batool F, Ahmed S, Haleem DJ: Dietary supplementations of amino acids: Evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex. J Coll Physicians Surg Pak, 2009c; 19: 139-45
12. Haleem DJ, Batool F, Khan NH et al: Differences in the effects of haloperidol and clozapine on rat brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit, 2002; 8: 3354-61
13. Fernstrom DJ: Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev, 1983; 63: 484-546
14. Park DH, Eve DJ, Borlongan CV et al: From the basics to application of cell therapy, a steppingstone to the conquest of neurodegeneration: a meeting report. Med Sci Monit, 2009; 15(2): RA23-31
15. Rafael H: Revascularization in some neurodegenerative diseases. Med Sci Monit, 2009; 15 (4): LE5-6
16. Galińska B, Szulc A, Tarasów E et al: Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit, 2009; 15 (2): CR82-88
17. Bidzan L, Pachalska M, Grochmal-Bach B et al: Behavioral and psychological symptoms in the preclinical stage of Alzheimer's disease. Med Sci Monit, 2008; 14 (9): CR473-79
18. Pachalska M, Grochmal-Bach B, MacQueen BD et al: Neuropsychological diagnosis and treatment after closed-head injury in a patient with a psychiatric history of schizophrenia. Med Sci Monit, 2008; 14(8): CS76-85
19. Fruntes V, Limosin F: Schizophrenia and viral infection during neurodevelopment: a pathogenesis model? Med Sci Monit, 2008; 14(6): RA71-77
20. Stone JM, Pilowsky LS: Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets, 2007; 6: 265-72
21. Bardin L, Kleven MS, Barnet-Grevez C et al: Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology, 2006; 31: 1869-79
22. Ellison G, See RE: Rats administered chronic neuroleptics develop oral movements which are similar in forms to those in humans with tardive dyskinesia. Psychopharmacology (Berl), 1989; 98: 564-66
23. Haleem DJ, Shireen E, Haleem MA: Somatodendritic and postsynaptic 5-HT-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiat, 2004; 28: 1323-29
24. Haleem DJ, Khan NH: Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiat, 2003; 27: 645-51
25. Egan MF, Hurd Y, Ferguson J et al: Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl), 1996; 127: 337-45
26. Farde L, Wiesel FA, Nordstrom AC, Sedvell G: D1 and D2 receptors occupancy during treatments with conventional and atypical neuroleptics. Psychopharmacology, 1986; 99: S28-S31
27. Waddington JL: Spontaneous orofacial movements-induced in rodents by very long term-neuroleptic administration: phenomenology, pathophysiology and putative relationship with tardive dyskinesia. Psychopharmacology (Berl), 1990; 101: 431-47
28. Porceddu ML, Origini E, Mele S, Biggio G: 3H-SCH-23390 binding sites in the rat substantia nigra: evidence for a presynaptic localization and innervation by dopamine. Life Sci, 1986; 39: 321-28
29. Naidu PS, Singh A, Kulkarni SK: Carvediol attenuates neurolepticinduced orofacial dyskinesia, possible antioxidant mechanism. Br J Pharmacol, 2002; 136: 193-200
30. Naidu PS, Singh A, Kulkarni SK: Effects of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfuctions. Phytother Res, 2006; 620: 140-46
31. Clausing P, Gough B, Holson RR et al: Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. J Pharmacol Exp Ther, 1995; 274; 614-21
32. Wright AM, Bempong J, Kirby ML et al: Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res, 1998; 788: 215-22
33. Sachdev PS: The current status of tardive dyskinesia. Aust NZJ Psychiatry, 2000; 34: 355-69
34. Casey DE: Tardive dyskinesia: Pathophysiology and animal models. J Clin Psychiat, 2002; 61: 5-9
35. Egan MF, Apud J, Wyatt RJ: Treatment of tardive dyskinesia. Schizophr Bull, 1979; 23: 583-609
36. Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y: The effect of chronic administration of sarizotan, 5-HT-1A agonist/D3/ D4 ligand on the haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiat, 2006; 30: 273-79
37. Haleem DJ, Samad N, Haleem MA: Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: atime-related study. Behav Pharmacol, 2007; 18: 147-53
38. Haleem DJ, Samad N, Haleem MA: Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol Biochem Behav, 2007; 87: 115-21
39. Halperin R, Guerin JJ, Davis KL: Regional differences in the induction of behavioral supersensitivity by prolonged treatment with a typical neuroleptic. Psychopharmacology, 1989; 98: 386-91
40. Tamminga CA, Dale JM, Goodman L et al: Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia; a study in three rat strains. Psychopharmacology (Berl), 1990; 102: 474-78
41. Xu Y, Li G, Han C, Sun L et al: Protective effects of Hippophae rhamnoides L. juice on lead-induced neurotoxicity in mice. Biol Pharm Bull, 2005; 28: 490-94
42. Naidu PS, Kulkarni SK: Effect of 5-HT-1A and 5-HT-2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol, 2001; 428: 81-86.